Pharmacy News

AstraZeneca’s drug Tagrisso gets China nod for early lung cancer treatment, Health News, ET HealthWorld

AstraZeneca Plc said on Wednesday that China’s health regulator expanded the use of Tagrisso, the British drugmaker‘s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.

China’s National Medical Products Administration (NMPA) approved Tagrisso as an adjuvant therapy for patients with early-stage lung cancer who have a mutation of the EGFR gene, AstraZeneca said.

The drug is now approved to treat early-stage lung cancer in more than a dozen countries, including, most recently, in the United States.

The drugmaker said the Chinese approval was based on positive results from a late-stage trial that showed Tagrisso cut the risk of disease recurrence or death by 83%.

The EGFR mutation is found in about a quarter of global lung cancer cases, and older generation of EGFR inhibitors include Roche‘s Tarceva and AstraZeneca’s own Iressa.

Follow and connect with us on , Facebook, Linkedin

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.